Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Carmen Muñiz, Lourdes Martín-Martín, Antonio López, Blanca Sánchez-González, Antonio Salar, Julia Almeida, Juan Manuel Sancho, José María Ribera, Cecilia Heras, Francisco Javier Peñalver, Marta Gómez, Eva González-Barca, Natalia Alonso, Belén Navarro, Teresa Olave, Francisco Sala, Eulogio Conde, José Antonio Márquez, Elena Cabezudo, Antonia CladeraMaría García-Malo, María Dolores Caballero, Alberto Orfao

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)


Flow cytometry (FCM) ismore sensitive than conventional cytology for detection of occult leptomeningeal lymphoma; however, some FCM-negative patients show central nervous system (CNS) recurrence. Here, we evaluated the cerebrospinal fluid (CSF) levels of 13 B-cell-associated markers and their contribution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL) and 22 Burkitt lymphomas (BLs). From all markers tested, CD19 wasthe most informative. Thus, higher soluble CD19 (sCD19) levels were associated with a greater frequency of neurological symptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL; sCD19 emerged as a powerful predictor of event-free and overall survival in DLBCL and BL, particularly when combined with FCM detection of CNS disease. These results support the utility of combined FCM detection of lymphoma cells and assessment of sCD19 levels in CSF, for more accurate identification of CNS disease in DLBCL and BL patients. © 2014 by The American Society of Hematology.
Original languageEnglish
Pages (from-to)1864-1869
Issue number12
Publication statusPublished - 20 Mar 2014


Dive into the research topics of 'Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome'. Together they form a unique fingerprint.

Cite this